Intelligent Bio Solutions Q1 FY27 net loss narrows 11% to $2.67 million; revenue rises 25% to $1.39 million
INBS•Intelligent Bio Solutions’ fiscal first-quarter FY27 net loss narrowed 11% year over year to $2.67 million, while revenue rose 25% year over year and 21% sequentially to a record $1.39 million. Gross margin reached 54.5%, and the company submitted an FDA 510(k) notification seeking codeine-detection clearance.
1. Quarterly results
Intelligent Bio Solutions reported a fiscal first-quarter FY27 net loss of $2.67 million, down 11% year over year. Revenue increased 25% year over year and 21% sequentially to a record $1.39 million, while gross profit margin reached 54.5%, reflecting manufacturing efficiencies and a higher share of higher-margin cartridge revenue.
2. FDA submission
The company submitted its FDA 510(k) notification on September 9, 2026, seeking clearance for its fingerprint drug-screening system to detect codeine.
